– Lead program, ADAIR, advancing toward completion of patient enrollment and treatment in ongoing SEAL study – Selection of final formulation completed for second development program, ADMIR – Company’s two…
Read More
– Inaugural appointments include globally renowned leaders and experts on attention-deficit/hyperactivity disorder (ADHD) and stimulant abuse PHILADELPHIA, PA, Sept. 14, 2021 — Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the…
Live video webcast with David Baker, President and CEO of Vallon, on Wednesday, August 18th 12:30 PM ET PHILADELPHIA, PA, Aug. 11, 2021 — Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon”…
– Company continues to drive enrollment in pivotal intranasal abuse study evaluating ADAIR toward completion before year-end 2021 – ADAIR targeting the large and growing Adderall® segment of the ~$9…
– Patent bolsters intellectual property protection as Company’s partner, MEDICE, works to develop and potentially commercialize ADAIR in Europe and the UK PHILADELPHIA, PA, July 13, 2021 — Vallon Pharmaceuticals…
– Company remains on track to report pivotal data from lead program, ADAIR, in second half 2021 – Novel abuse-deterrent platform technology enables pipeline expansion opportunities across multiple drugs and…
– Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big four accounting firm PHILADELPHIA, PA, May 11, 2021 — Vallon…
Live video webcast with David Baker, President and CEO of Vallon on Tuesday, May 18, 2021 at 4:15 PM ET PHILADELPHIA, PA, May 07, 2021 — Vallon Pharmaceuticals Inc. (NASDAQ:…
David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel on April 29th at 10:30 AM ET PHILADELPHIA, PA, April 26, 2021 — Vallon…
– Ongoing ADAIR SEAL study on target for pivotal data readout in second half of 2021– Target NDA filing in Q2 2022 for a potential abuse-deterrent alternative to commercially available…
